NEW YORK, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and ...
Please provide your email address to receive an email when new articles are posted on . The addition of the novel monoclonal antibody hu14.18K322A to induction chemotherapy significantly improved ...
From Bambino Gesù Children's Hospital in Rome comes a report that a third-generation CAR T cell therapy targeting GD2, designated GD2–CART01, induced durable remissions and long-term survival in ...
Y-mAbs announces positive Phase 1 Trial 1001 results for GD2-SADA in cancer, plans further studies with optimized radiohapten "Proteus." Y-mAbs Therapeutics, Inc. announced positive results from the ...
Anti-disialoganglioside (GD2)-targeted third-generation chimeric antigen receptor T cells (GD2-CART01) have shown promising efficacy in children with high-risk metastatic, relapsed, and refractory ...
The Buffalo Drivestation DDR 2TB (HD-GD2.0U3) adds DDR3 system memory to make a non-Flash hybrid external drive. It's faster than regular spinning hard drives, but a lot less expensive than SSD-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback